Faculty
Years of research from USC Dornsife’s Chien-Ping Ko have led to the FDA’s approval of risdiplam, a cheaper and easier-to-administer drug for children with spinal muscular atrophy. [3 min read]
Years of research from USC Dornsife’s Chien-Ping Ko have led to the FDA’s approval of risdiplam, a cheaper and easier-to-administer drug for children with spinal muscular atrophy. [3 min read]
